	US 11,738,080 B2
	Production of flu vaccine in Myceliophthora thermophila
Mark Emalfarb, Jupiter, FL (US); Teunis Cornelis Verwoerd, Renkum (NL); Mark R. Alfenito, Redwood City, CA (US); Mark Baer, San Francisco, CA (US); Isabelle Legastelois, Lentilly (FR); Marie-Pierre Kazek, Brindas (FR); Marie-Clotilde Bernard, Charbonnieres les Bains (FR); Jean Dubayle, Ville sur Jarnioux (FR); and Richard Kensinger, Henryville, PA (US)
Assigned to DYADIC INTERNATIONAL INC., Jupiter, FL (US)
Appl. No. 16/640,483
Filed by DYADIC INTERNATIONAL INC., Jupiter, FL (US)
PCT Filed Aug. 9, 2018, PCT No. PCT/IB2018/056003 § 371(c)(1), (2) Date Feb. 20, 2020, PCT Pub. No. WO2019/038623, PCT Pub. Date Feb. 28, 2019.
Claims priority of provisional application 62/547,885, filed on Aug. 21, 2017.
Prior Publication US 2020/0215183 A1, Jul. 9, 2020
Int. Cl. A61K 39/145 (2006.01); C12N 1/14 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01); C12R 1/645 (2006.01)

CPC A61K 39/145 (2013.01) [C12N 1/145 (2021.05); A61K 2039/5256 (2013.01); C12N 7/00 (2013.01); C12N 2760/16251 (2013.01); C12N 2760/18134 (2013.01); C12R 2001/645 (2021.05)]

20 Claims

1. A Myceliophthora thermophila C1 genetically-modified to produce an influenza virus surface protein, comprising an expression construct comprising a nucleic acid sequence encoding the influenza virus surface protein operably linked to at least one C1 regulatory sequence, wherein the influenza virus surface protein comprises its ectodomain and transmembrane domain and is expressed in the C1 as a membrane-bound protein.